We found that regorafenib, as well as other TKIs, induces elevated HLA-I expression in HCC cells through enhancement of STAT1 activation by IFNγ, and that downregulation of MAPK signaling might be a mechanism by which TKIs promote HLA-I induction. This evidence concerns the gene IFNG and hepatocellular carcinoma.